AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04781140
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered once daily
Trial: NCT05861648
Drug: Folic Acid Oral Tablet
RxNorm normalized name: folic acid Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary Supplement: Folic acid 2.5mg/day
Trial: NCT05344911
Drug: Propofol combined with remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthesia induction: midazolam 0.02 mg/kg, propofol（TCI） 3 μ g/mL, remifentanil 1μ g/kg and rocuronium 0.6 mg/kg . Anesthesia maintenance: target-controlled infusion of propofol combined with remifentanil(0.1-0.3ug/kg/min)
Trial: NCT06569056
Drug: HRS-8427 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing frequency: for 7-14 days; dose adjustments of subjects with reduced function include reduced doses
Trial: NCT06565572
Drug: nL-FLVC-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nL-FLVC-001 is an antisense oligonucleotide that will be injected into the vitreous
Trial: NCT06556511
Drug: Zinc Sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc is administered at a dose of 10 mg per day for children under the age of 6 months, and 20 mg per day for children above the age of 6 months accompanied with standard therapy in the zinc group for a period of 10 days.
Trial: NCT06556511
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered with standard therapy in the placebo group for a period of 10 days.
Trial: NCT05825781
Drug: Perjeta®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v.
Trial: NCT05247593
Drug: Dayingpian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The actual dosage of Dayingpian is adjusted according to the patient's condition. The recommended dosage of Dayingpian is 5-10 tablets each time, 2-3 times a day.
Trial: NCT05247593
Drug: conventional mood stabilizers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the group are treated with the standard level of conventional mood stabilizers provided by psychiatrists according to treatment guidelines for bipolar disorder.
Trial: NCT00037622
Drug: ACH-126, 443 (beta-L-Fd4C)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04777409
Drug: Placebo (semaglutide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo (semaglutide) once-daily. The study will last for up to 173 weeks
Trial: NCT06568094
Drug: SHR2554 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR2554 tablets
Trial: NCT04629248
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premedication: Acetaminophen (650-1000 mg, or equivalent dose of a similar agent) PO or IV will be administered between 30 and 60 minutes prior to the obinutuzumab infusion in all study periods.
Trial: NCT05431153
Drug: Single dose of PF-07104091 as Tablet Formulation A (Treatment A)
RxNorm normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of PF-07104091 as Tablet Formulation A administered under fasting conditions.
Trial: NCT05431153
Drug: Single dose of PF-07104091 as Tablet Formulation B (Treatment B)
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of PF-07104091 as Tablet Formulation B administered under fasting conditions.
Trial: NCT05431153
Drug: Single dose of PF-07104091 as Tablet Formulation C (Treatment C)
RxNorm normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of PF-07104091 as Tablet Formulation C administered under fasting conditions.
Trial: NCT05431153
Drug: Single dose of PF-07104091 as Tablet Formulation D (Treatment D)
RxNorm normalized name: Rho(D) - Unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of PF-07104091 as Tablet Formulation D administered under fasting conditions.
Trial: NCT05431153
Drug: Single dose of PF-07104091 as Tablet Formulation C (Treatment E)
RxNorm normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of PF-07104091 as Tablet Formulation C administered under fed conditions.
Trial: NCT05123586
Drug: LY3361237
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT05123586
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT05303064
Drug: OLZ/SAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OLZ/SAM refers to the fixed dose combination of olanzapine and samidorphan. The starting dose of olanzapine will be 2.5 mg/day or 5 mg/day at the discretion of the Investigator with a maximum daily dose of 20mg/day. The starting dose of samidorphan will be 5 or 10 mg.
Trial: NCT04963088
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m² orally twice daily (bid) Days 1 through 14 (14 days total) during each 21-day cycle. Capecitabine will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.
Trial: NCT06529809
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy are not dictated by the protocol and will follow standard of care guidelines
Trial: NCT05021263
Drug: IV Medications
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV magnesium sulfate, used to replete magnesium stores
Trial: NCT06384222
Drug: Hyperpolarized [1-13C] pyruvate (HP 13C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05752149
Drug: CRGD-ZW800-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of study drug at lesat 2h prior to surgery
Trial: NCT05067257
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle solution
Trial: NCT05753384
Drug: treatment of TKI in CML
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continued treatment with TKI at randomization a then stopped treatment 12 months after randomization
Trial: NCT04966832
Drug: XW10508
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XW10508 capsules or tablets
Trial: NCT06511908
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 1 and 2 Control Intervention
Trial: NCT05109728
Drug: [177Lu]Lu-DOTA-TATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: \[177Lu\]Lu-DOTA-TATE, dose level 0 (150mCi) administered every 4 weeks. Three provisional dose levels (Dose level +2: 250 mCi; Dose level +1: 200 mCi; Dose level -1: 100 mCi) will be assessed.~Group 3: \[177Lu\]Lu-DOTA-TATE, dose level 0 (150mCi) administered every 3 weeks. Three provisional dose levels (Dose level +2: 250 mCi; Dose level +1: 200 mCi; Dose level -1: 100 mCi) will be assessed.
Trial: NCT05109728
Drug: [68Ga]Ga-DOTA-TATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 MBq/kg of body weight (0.054 mCi/kg), with a minimum dose of 100 MBq (2.7 mCi) and maximum dose of 200 MBq (5.4 mCi)
Trial: NCT06122649
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT04783766
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo- Tablets
Trial: NCT06109558
Drug: LMV-12(HE003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 cycle was 28 days. LMV-12(HE003), 30mg or 60mg, continuously for 21 days, and the drug was discontinued for 7 days. Osimertinib, 80mg, continuously for 28 days.
Trial: NCT06057519
Drug: Standard dose rifampicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose rifampicin
Trial: NCT04838613
Drug: [18F]CTT1057
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous dose of approximately 370 Mega-Becquerel (MBq) and subsequent PET/CT scan
Trial: NCT04838613
Drug: [68Ga]Ga-PSMA-11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous dose of approximately 150 MBq and subsequent PET/CT scan
Trial: NCT06289998
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects are administrated to placebo in daily for 52 weeks.
Trial: NCT05325099
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (subcutaneous injection) QOD x 3 times
Trial: NCT05128409
Drug: XKH001 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5mg/kg: 3Subjects,1Sentinel Participants 1.67mg/kg: 6Subjects, ,1Sentinel Participants 3.34mg/kg: 6Subjects,1Sentinel Participants 5.0mg/kg: 6Subjects, ,1Sentinel Participants 10.0mg/kg: 6Subjects,1Sentinel Participants
Trial: NCT05128409
Drug: XKH001Placebo Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.67mg/kg: 2Subjects,1Sentinel Participants 3.34mg/kg: 2Subjects,1Sentinel Participants 5.0mg/kg: 2Subjects,1Sentinel Participants 10.0mg/kg: 2Subjects, 1Sentinel Participants
Trial: NCT04901078
Drug: KNX100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KNX100 will be provided in capsule form as 5, 25 and 100 mg capsules for oral administration. Study drug will be encapsulated in hydroxypropyl methylcellulose (HPMC) dark green opaque size 0 capsules and packaged in 100 mL high density polyethylene (HDPE) bottles with polypropylene (PP) twist-off closures.
Trial: NCT05904912
Drug: Postoperative analgesia management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 0.5 mg/kg tramodol and 1 gr paracetamol will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered iparacetamol iv 1 gr 3x1. Postoperative patient evaluation will be performed by another pain nurse who is unaware of the procedure. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.
Trial: NCT06155604
Drug: Standard maintenance therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 5-7.5 mg daily alone or in combination with Mycophenolate mofetil (\<=1.5 g/D) or Azathioprine (\<=150 mg/D)
Trial: NCT06283550
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet
Trial: NCT05889871
Drug: Standard endocrine therapy plus Apatinib
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard endocrine therapy plus Apatinib
Trial: NCT04886739
Drug: CGB-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gel
Trial: NCT04886739
Drug: Vehicle Gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gel
Trial: NCT05540288
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Week 1: 1 tablet/d~Week 2:~1. In the absence of ARs or in the presence of grade 1 or 2 ARs, 2 tablets/d~2. In the presence of grade 3 ARs, 1 tablet/d~3. In the presence of grade 4 ARs, the treatment will be stopped immediately.~Week 3 to week 5:~1. In case of acceptable safety profile at the dosage of 1 tablet/d during week 2, the treatment will be maintained at the same dosage~2. In the presence of sustained grade 3 ARs at the dosage of 1 tablet/d during week 2, the treatment will be stopped.~3. In case of acceptable safety profile at the dosage of 2 tablets/d during week 2, the treatment will be maintained at the same dosage~4. In the presence of grade 3 ARs at the dosage of 2 tablets/d during week 2, the treatment dosage will be decreased at 1 tablet/d~5. Whatever the dosage during week 2, in the presence of grade 4 ARs, the treatment will be stopped immediately.
Trial: NCT05501678
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo given orally
Trial: NCT05623839
Drug: LY3305677
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT05623839
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT05748197
Drug: Conditioning chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine 30 mg/m2 daily for 3 days and cyclophosphamide 500 mg/m2 daily for 3 days.
Trial: NCT04335032
Drug: Eicosapentaenoic acid gastro-resistant capsules
RxNorm normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: same as in arm/group description
Trial: NCT04335032
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: same as in arm/group description
Trial: NCT05960942
Drug: propofol-sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In group PS, sufentanil was administered intravenously at a dose of 0.2 μg.kg-1, then 2.0 mg.kg-1 propofol was intravenously injected.
Trial: NCT05092347
Drug: Vonsetamig
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by intravenous (IV) infusion
Trial: NCT06802081
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly subcutaneous injections starting with dose 2.5mg, then increase dose by 2.5mg at week 4 (5mg), week 8 (7.5mg) and at week 12 (10mg).
Trial: NCT05083481
Drug: ASP1570
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT05083481
Drug: Trifluridine + Tipiracil
RxNorm normalized name: tipiracil / trifluridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Administration
Trial: NCT06503016
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline solution of NaCl 0.9%
Trial: NCT03899636
Drug: Modified FOLFIRINOX Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy regimen of leucovorin, fluorouracil, irinotecan, and oxaliplatin
Trial: NCT05592262
Drug: SHR2554
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On an empty stomach - after meals
Trial: NCT05592262
Drug: SHR2554
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After meals - on an empty stomach
Trial: NCT05136287
Drug: GLP-1 receptor agonist
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients are included after GLP1 agonists prescription , at the first dispensation
Trial: NCT04487860
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT06354712
Drug: N-Acetyl-Cysteine with Institutional standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A potent antioxidant and anti-inflammatory drug (A precursor of the endogenous antioxidant glutathione)
Trial: NCT06354712
Drug: Institutional standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzydamine Mouthwash
Trial: NCT05670054
Drug: comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival
Trial: NCT06401083
Drug: Caffeine citrate
RxNorm normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg/kg caffeine-citrate before the planned extubation.
Trial: NCT05583812
Drug: FB2001 for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FB2001 once or twice daily inhalation
Trial: NCT05583812
Drug: FB2001 for inhalation placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FB2001 placebo once or twice daily inhalation
Trial: NCT06536491
Drug: EC-104 low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection
Trial: NCT06319963
Drug: Two IM injections Lenti-HPV-07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two Lenti-HPV-07 intramuscular injections one month apart
Trial: NCT06319963
Drug: One IM injection Lenti-HPV-07
RxNorm normalized name: Gel-One Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single intramuscular injection prior to receiving a standard of care 28 days at least after the injection.
Trial: NCT05719376
Drug: control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferritin\<100, TSAT\<20 : Monofer 200mg IV, twice/ Ferritin 100\~200, TSAT\<20 : Monofer 200mg IV, once / Ferritin 201\~500, TSAT\<20 : Monofer 100mg IV, once / Not administer in any other case
Trial: NCT04873583
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous treatment will be immediately followed by oral tapering with Prednisolone.~Oral Prednisolone, 2 weeks (week 1 and 2) Dose: 1 mg/kg/day (max 40 mg/day) Oral Prednisolone, 2 weeks (week 3 and 4) Dose: 0.5 mg/kg/day (max 20 mg/day)
Trial: NCT05960864
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If we find any behavior that affects the safety of patients in the experiment, we will stop
Trial: NCT05868109
Drug: inhaled nitric oxide (iNO)
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In patients randomized to the this arm, iNO will be delivered into the ventilator circuit through the endotracheal tube or tracheostomy. The dose will be 80 ppm during chest compressions and reduced to 20 ppm immediately following ROC. If the patient is enrolled following ROC, the dose will be 20 ppm. Dose modifications will occur if there is toxicity or if there is a clinical concern. The iNO or sham will be continued for 72 hours or until extubation.
Trial: NCT05868109
Drug: Sham
RxNorm normalized name: SHAMPOO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In patients randomized to sham, the iNO delivery device will be connected to the ventilator circuit or manual ventilation bag but flow of iNO will not be turned on. For the purposes of patient safety and to maintain blinding, the respiratory therapists (RTs) will continue checks of gas flow, flow adjustments and change iNO gas tanks at rates like routine clinical procedures on patients treated with iNO or sham.
Trial: NCT06203275
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with type 2 diabetes treated with metformin based combined oral hypoglycemic ( metformin plus DDP4 inhibitor or metformin plus sulfonylureas or metformin plus GLP-1 analogues) plus placebo daily
Trial: NCT06253130
Drug: IMP1734
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PARP1 selective inhibitor
Trial: NCT05735483
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04799158
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally via capsules
Trial: NCT06559163
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04680052
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo will be administered IV for 12 cycles
Trial: NCT06189508
Drug: NXT007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In all groups, the NXT007 single dose administration will occur in the morning of Day 1 under fasted conditions. Study treatment will occur via the route of administration and at the site of injection specified for each group.
Trial: NCT04620603
Drug: Standard-of-Care Immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard or care immunotherapy will be administered at the FDA approved dose via IV infusion.
Trial: NCT05218096
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet.
Trial: NCT05238493
Drug: VEL-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention administered via subcutaneous injection or 1-hour intravenous infusion on Day 1
Trial: NCT05238493
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention administered via subcutaneous injection or 1-hour intravenous infusion on Day 1
Trial: NCT05335499
Drug: TAS5315 Dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment period: oral administration for 12 weeks, QD
Trial: NCT05335499
Drug: TAS5315 Dose 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment period: oral administration for 12 weeks, QD
Trial: NCT05335499
Drug: TAS5315 Dose 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment period: oral administration for 12 weeks, QD
Trial: NCT05335499
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Screening period: oral administration for 2 weeks, QD~* Treatment period: oral administration for 12 weeks, QD
Trial: NCT06089837
Drug: EC5026 oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 sequential cohorts of 8 subjects randomly assigned to receive multiple ascending oral doses of EC5026 (n=6 per cohort) or matching placebo (n=2 per cohort) for 7 consecutive days.~Oral doses of EC5026 tested in each cohort:~4 mg loading dose on Day 1 / 2 mg Maintenance dose on Days 2-7 (Cohort 1) 8 mg loading dose on Day 1 / 4 mg Maintenance dose on Days 2-7 (Cohort 2)
Trial: NCT06089837
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 sequential cohorts of 8 subjects randomly assigned to receive multiple ascending oral doses of EC5026 (n=6 per cohort) or matching placebo (n=2 per cohort) for 7 consecutive days. Subject assigned to the Placebo Arm will receive 7 days of matching placebo oral tablets in each Cohort.
Trial: NCT05485155
Drug: Alpha-proteinase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion at 120 mg/kg body weight dose/week for 4 weeks for a total of 4 infusions.
Trial: NCT05709249
Drug: placebo (XLJDOD mimetic agent)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The course of placebo in control group will be in accordance with that of XLJDOD in intervention group.